JP2024513798A - Ｓｈｐ２阻害剤の結晶形態 - Google Patents

Ｓｈｐ２阻害剤の結晶形態 Download PDF

Info

Publication number
JP2024513798A
JP2024513798A JP2023559680A JP2023559680A JP2024513798A JP 2024513798 A JP2024513798 A JP 2024513798A JP 2023559680 A JP2023559680 A JP 2023559680A JP 2023559680 A JP2023559680 A JP 2023559680A JP 2024513798 A JP2024513798 A JP 2024513798A
Authority
JP
Japan
Prior art keywords
crystalline form
dihydrospiro
amino
piperidine
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513798A5 (enExample
Inventor
キートン ブラウン カティー
キース グッドウィン アーロン
Original Assignee
アレイ バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ インコーポレイテッド filed Critical アレイ バイオファーマ インコーポレイテッド
Publication of JP2024513798A publication Critical patent/JP2024513798A/ja
Publication of JP2024513798A5 publication Critical patent/JP2024513798A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023559680A 2021-04-01 2022-03-30 Ｓｈｐ２阻害剤の結晶形態 Pending JP2024513798A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169340P 2021-04-01 2021-04-01
US63/169,340 2021-04-01
US202263321902P 2022-03-21 2022-03-21
US63/321,902 2022-03-21
PCT/IB2022/052982 WO2022208408A1 (en) 2021-04-01 2022-03-30 Crystalline form of a shp2 inhibitor

Publications (2)

Publication Number Publication Date
JP2024513798A true JP2024513798A (ja) 2024-03-27
JP2024513798A5 JP2024513798A5 (enExample) 2025-03-19

Family

ID=81327112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559680A Pending JP2024513798A (ja) 2021-04-01 2022-03-30 Ｓｈｐ２阻害剤の結晶形態

Country Status (9)

Country Link
US (1) US20240190843A1 (enExample)
EP (1) EP4313307A1 (enExample)
JP (1) JP2024513798A (enExample)
KR (1) KR20230165309A (enExample)
AU (1) AU2022252094B2 (enExample)
BR (1) BR112023019479A2 (enExample)
CA (1) CA3215295A1 (enExample)
MX (1) MX2023011664A (enExample)
WO (1) WO2022208408A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391708B2 (en) 2019-07-18 2025-08-19 Tapi Croatia Industries Ltd Crystalline Lorlatinib : fumaric acid and solid state form thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
JP2004512333A (ja) * 2000-10-20 2004-04-22 イーライ・リリー・アンド・カンパニー 新規な結晶形の６−ヒドロキシ−３−（４−［２−（ピペリジン−１−イル）エトキシ］フェノキシ）−２−（４−メトキシフェニル）ベンゾ［ｂ］チオフェン塩酸塩
WO2006137450A1 (ja) * 2005-06-21 2006-12-28 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶、その製造方法及びその使用
JP2018517752A (ja) * 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
JP2019527728A (ja) * 2016-07-12 2019-10-03 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン
JP2020515538A (ja) * 2017-03-23 2020-05-28 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
WO2020201991A1 (en) * 2019-04-02 2020-10-08 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
JP2020536881A (ja) * 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
JP2021506776A (ja) * 2017-12-15 2021-02-22 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
JP2004512333A (ja) * 2000-10-20 2004-04-22 イーライ・リリー・アンド・カンパニー 新規な結晶形の６−ヒドロキシ−３−（４−［２−（ピペリジン−１−イル）エトキシ］フェノキシ）−２−（４−メトキシフェニル）ベンゾ［ｂ］チオフェン塩酸塩
WO2006137450A1 (ja) * 2005-06-21 2006-12-28 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶、その製造方法及びその使用
JP2018517752A (ja) * 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
JP2019527728A (ja) * 2016-07-12 2019-10-03 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン
JP2020515538A (ja) * 2017-03-23 2020-05-28 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
JP2020536881A (ja) * 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
JP2021506776A (ja) * 2017-12-15 2021-02-22 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物
WO2020201991A1 (en) * 2019-04-02 2020-10-08 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
小野 誠: "医薬品の結晶形態スクリーニング", ファルマシア, vol. 47, no. 11, JPN6016047656, 2011, pages 1014 - 1018, ISSN: 0005738342 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005738344 *
杉本 功 他: "溶媒和物、非晶質固体と医薬品製剤", 粉体工学会誌, vol. 22, no. 2, JPN6017004373, 1985, pages 85 - 97, ISSN: 0005738343 *

Also Published As

Publication number Publication date
AU2022252094A1 (en) 2023-10-12
WO2022208408A1 (en) 2022-10-06
EP4313307A1 (en) 2024-02-07
AU2022252094B2 (en) 2024-10-17
CA3215295A1 (en) 2022-10-06
BR112023019479A2 (pt) 2023-12-05
MX2023011664A (es) 2023-10-11
KR20230165309A (ko) 2023-12-05
US20240190843A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
AU2022252094B2 (en) Crystalline form of a shp2 inhibitor
CN111848586B (zh) 用于抑制jak的化合物和方法
JP2024512624A (ja) Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
JP6110817B2 (ja) 大環状キナーゼ阻害剤の固体形態
JP6218253B2 (ja) ロルラチニブ遊離塩基の結晶形態
WO2019134539A1 (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
CA2927830A1 (en) Quinazolinone and isoquinolinone derivative
WO2021057853A1 (en) Aza-quinoline compounds and uses thereof
WO2022002100A1 (zh) 新型苯并咪唑化合物
CN117460725A (zh) Shp2抑制剂的晶型
HK40101911A (zh) Shp2抑制剂的晶型
EP4577542A1 (en) Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
JP2025509818A (ja) Ｓｈｐ２阻害剤の結晶性塩形態
RU2826000C1 (ru) 3,4-дигидро-2,7-нафтиридин-1,6(2h,7h)-дионы в качестве ингибиторов mek
HK40112682A (zh) Shp2抑制剂的结晶盐形式
JP2005162673A (ja) 二環性ピリミジン誘導体
WO2022153157A1 (en) A crystalline form of 2-((4-amino-2-(ethoxymethyl)-6,7-dimethyl-1 h-imidazo[4,5-c]pyridin-1-yl)methyl)-2-methylpropane-1,3-diol free base
CN119301129A (zh) 三环类化合物及其用途
TW202406539A (zh) 藥物組合及其用途
HK40119524A (zh) 三环类化合物及其用途
BR112023019849B1 (pt) 3,4-di-hidro-2,7- naftiridina-1,6(2h,7h)-dionas, composições que os compreendem, usos dos mesmos, e kits
TW202328152A (zh) 氮雜內醯胺化合物之晶型
EA047982B1 (ru) 3,4-дигидро-2,7-нафтиридин-1,6(2h,7h)-дионы в качестве ингибиторов mek
HK40130960A (zh) 三环类化合物及其用途
HK40026768A (en) Compounds and methods for inhibiting jak

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260209